AXNX - Axonics acquires tech linked to sacral neuromodulation procedure

2023-04-24 06:22:01 ET

Axonics ( NASDAQ: AXNX ) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering.

The company acquired the assets of Radian from Intermed Labs for undisclosed terms.

SNM is a minimally invasive therapy used to help restore normal bladder or bowel function.

The company noted that the technology has the potential to reduce procedure time and help with a more accurate placement which can increase physicians’ confidence in the SNM procedure and drive increased therapy adoption and permanent implant conversion rates.

With a standard x-ray image of a patient's pelvis, a physician can use the software to decide the location for needle entry and lead placement based on the person's specific anatomy.

The technology can be implemented in existing workflows as it takes only minutes to use and requires minimal training, according to the company.

Axonics expects the product to receive FDA clearance and be commercially available in mid-2024.

"We expect the Radian technology will improve patient comfort, increase physician confidence and SNM access, simplify the learning curve for physicians new to SNM, and increase PNE trial success rates, which should ultimately result in more adults being treated with our life-changing SNM therapy," said Axonics CEO Raymond Cohen.

For further details see: